Arsenic trioxide: An anti cancer missile with multiple warheads

Hematology

Volumn 10, Issue 3, 2005, Pages 205-213

  Gazitt, Yair ^a   Akay, Cagla ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

AIF; Apoptosis; Arsenic trioxide; BID; p53; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; APOPTOSIS INHIBITOR; ARSENIC TRIOXIDE; ASCORBIC ACID; BCR ABL PROTEIN; BORTEZOMIB; CASPASE 3; CASPASE 9; GLUTATHIONE; HYBRID PROTEIN; HYDROGEN PEROXIDE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STRESS ACTIVATED PROTEIN KINASE; THALIDOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; DNA FRAGMENT; FLAVOPROTEIN; MEMBRANE PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PDCD8 PROTEIN, HUMAN;

ACUTE PREMYELOCYTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CELL CYCLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MEMBRANE DEPOLARIZATION; CHROMATIN CONDENSATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOWNSTREAM PROCESSING; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; LEUKEMIA; MITOCHONDRIAL MEMBRANE; MITOSIS INHIBITION; MYELODYSPLASTIC SYNDROME; MYELOMA CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG EFFECT; METABOLISM; MITOSIS; PROMYELOCYTIC LEUKEMIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; ARSENICALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA FRAGMENTATION; FLAVOPROTEINS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MEMBRANE PROTEINS; MITOSIS; OXIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 25144469413     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330500067090     Document Type: Review

References (140)

1. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052-1061.
2. Mervis J. Ancient remedy performs new tricks. Science 1996;273:578-582.
3. Look AT. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. J Natl Cancer Inst 1998;90:86-88.
4. Gallagher RE. Arsenic - new life for an old potion. N Engl J Med 1998;339:1389-1391.
5. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell Jr., RP. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-1348.
6. Warrell Jr., RP. Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica. 1999;84:75-77.
7. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de The H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-1052.
8. Tamm I, Paternostro G, Zapata JM. Treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1999;40:1043, discussion 1044-1045.
9. Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z. Long-term survival and prognostic study in acute promyelocytic leukemia treated with ATRA, chemotherapy, and As2O3: An experience of 120 patients. Int J Hematol 1999;70:248-260.
10. Slack JL, Rusiniak ME. Current issues in the management of acute promyelocytic leukemia. Ann Hematol 2000;79:227-238.
11. Wang ZY, Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol 2000;1:101-106.
12. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. Semin Hematol 2001;38:26-36.
13. Cohen MH, Hirschfeld S, Susan FH, Ibrahim A, Johnson JR, O'Leary JJ, White RM, Williams GA, Pazdur R. Drug approval summaries: Arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001;6:4-11.
14. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell Jr, RP. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-3860.
15. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001;20:7146-7153.
16. Mayorga J, Richardson-Hardin C, Dicke KA. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. Clin J Oncol Nurs 2002;6:341-346.
17. Tallman MS, Nabhan C. Management of acute promyelocytic leukemia. Curr Oncol Rep 2002;4:381-389.
18. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002;2:705-713.
19. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experience. Am J Hematol 2002;70:292-299.
20. Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ. Expanding the use of arsenic trioxide: Leukemias and beyond. Semin Hematol 2002;39(2 Suppl. 1): 22-26.
21. Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002;39(2 Suppl. 1):8-13.
22. Au WY, Chim CS, Lie AK, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002;117:130-132.
23. Huan SY, Yang CH, Chen YC. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: A useful salvage therapy. Leuk Lymphoma 2000;38:283-293.
24. Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002;16:1835-1837.
25. Cheson BD, Zwiebel JA, Dancey J, Murgo A. Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 2000;27:560-577.
26. Vuky J, Yu R, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investig New Drugs 2002;20:327-330.
27. Shen GL, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052-1061.
28. Gianni M, de The H. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. Leukemia 1999;13:739-749.
29. Rego EM, He LZ, Warrell RP, Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 2000;97:10173-11018.
30. Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, Ruthardt M. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999;19:5170-5178.
31. Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: Induction of apoptosis and inhibition of proliferation. Br J Haematol 2002;116:555-563.
32. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-3353.
33. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Paolo Pandolfi P. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2000;2:730-736.
34. Warrell RP, Jr. Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica. 1999;84: 75-77.
35. Li J, Chen P, Sinogeeva N, Gorospe M, Wersto RP, Chrest FJ, Barnes J, Liu Y. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 2002;277:49504-49510.
36. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, Chen GQ. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia. 2003;17:1333-1337.
37. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000;14:262-270.
38. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102-2111.
39. Davison K, Mann KK, Miller WH, Jr. Arsenic trioxide: Mechanisms of action. Semin Hematol 2002;39(2 Suppl. 1): 3-7.
40. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-277.
41. Miller WH, Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002;7(Suppl. 1):14-19.
42. Miller WH, Jr., Waxman S. Differentiation induction as a treatment for hematologic malignancies. Oncogene 2002;21(21):3496-3506.
43. Gurr JR, Bau DT, Liu F, Lynn S, Jan KY. Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells. Mol Pharmacol 1999;56(1):102-109.
44. Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, Naoe T. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000;14:1743-1750.
45. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, Platanias LC. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002;277:44988-44995.
46. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP, Jr., Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000;96:1525-1530.
47. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de The H. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998;91:4300-4310.
48. Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, Ikeda Y. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000;14:431-438.
49. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de The H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-1052.
50. Muto A, Kizaki M, Kawamura C, Matsushita H, Fukuchi Y, Umezawa A, Yamada T, Hata J, Hozumi N, Yamato K, Ito M, Ueyama Y, Ikeda Y. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. Leukemia 2001;15:1176-1184.
51. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia. Br J Haematol 2001;112:783-786.
52. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL. Blood 2000;95:1014-1022.
53. Shim MJ, Kim HJ, Yang SJ, Lee IS, Choi HI, Kim T. Arsenic trioxide induces apoptosis in CML K562 cells: Possible involvement of p38 MAP kinase. J Biochem Mol Biol 2002;35:377-383.
54. Puccetti E, Guller S, Orleth A, Bruggenolte N, Hoelzer D, Ottmann OG, Ruthardt M. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000;60:3409-3413.
55. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, Zamzami N, Xie Z, Reed J, Kroemer G. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249:413-421.
56. Park JW, Choi YJ, Jang MA, Baek SH, Lim JH, Passaniti T, Kwon TK. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 2001;6:726-734.
57. Iwama K, Nakajo S, Aiuchi T, Nakaya K. Apoptosis induced by arsenic trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of ERK and the Ca2 + -dependent production of superoxide. Int J Cancer 2001;92:518-526.
58. Choi YJ, Park JW, Suh SI, Mun KC, Bae JH, Song DK, Kim SP, Kwon TK. Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. Int J Oncol 2002;21:603-610.
59. Hu XM, Hirano T, Oka K. Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol 2003;51:119-126.
60. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, Lee YY. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest and induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000;60:3065-3071.
61. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658-3668.
62. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: Enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002;8:566-572.
63. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002;1:851-860.
64. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805-813.
65. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53 dependent G1 or G2/M cell cycle arrest, activation of caspase 8 or caspase 9 and synergy with APO2/Trail. Blood 2003;101:4078-4087.
66. Akay C, Gazitt Y. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle 2003;2:358-368.
67. Akay C, Thomas C, Gazitt Y. Arsenic trioxide and paclitaxel induce apoptosis by different mechanism. Cell Cycle 2004;3:324-334.
68. Ora I, Bondesson L, Jonsson C, Ljungberg J, Porn-Ares I, Garwicz S, Pahlman S. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000;277:179-185.
69. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999;455:59-62.
70. Shen ZY, Shen J, Cai WJ, Hong C, Zheng MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 2000;5:155-158.
71. Shen ZY, Shen WY, Chen MH, Shen J, Cai WJ, Zeng Y. Mitochondria, calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As2O3. Int J Mol Med 2002;9:385-390.
72. Shen ZY, Shen J, Li QS, Chen CY, Chen JY, Yi Z. Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide. World J Gastroenterol 2002;8:31-35.
73. Jiang X, Wong B, Yuen S, Jiang SH, Cho CH, Lai KC, Lin MC, Kung HF, Lam SK, Wong BC. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001;93:916-920.
74. Zhang TC, Cao EH, Li JF, Ma W, Qin JF. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 1999;35: 1258-1263.
75. Siu KP, Chan JY, Fung KP. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: Inhibition of proliferation and induction of apoptosis. Life Sci 2002; 71:275-285.
76. Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y. Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2002;291:861-867.
77. Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, Chun YJ, Lee SH, Hong SI, Rhee CH. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncolw 2002;21:57-63.
78. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Lee YY, Kim BK. Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 2001;18:249-255.
79. Chun YJ, Park IC, Park MJ, Woo SH, Hong SI, Chung HY, Kim TH, Lee YS, Rhee CH, Lee SJ. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). FEBS Lett 2002;519:195-200.
80. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6:4957-4964.
81. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001;61:5432-5440.
82. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma - characterizing its apoptotic pathway. Anticancer Drugs 2002;13:293-300.
83. Zhao S, Tsuchida T, Kawakami K, Shi C, Kawamoto K. Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol 2002;21:49-55.
84. Park WH, Cho YH, Jung CW, Park OJ, Kim K, Hyuck Im Y, Lee MH, Ki Kang W, Park K. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003;300: 230-235.
85. Chen GC, Guan LS, Hu WL, Wang ZY. Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells. Anticancer Res 2002;22(2A):633-638.
86. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E. Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 2002;73:61-73.
87. Deaglio S, Canella D, Baj G, Arnulfo A, Waxman S, Malavasi F. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. Leuk Res 2001;25:227-235.
88. Yuksel S, Saydam G, Uslu R, Sanli UA, Terzioglu E, Buyukececi F, Omay SB. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leuk Res 2002;26:391-398.
89. Mak NK, Wong RN, Leung KN, Fung M. Involvement of tumor necrosis factor α (TNF-α) in arsenic trioxide induced apoptotic cell death of murine myeloid leukemia cells. Toxicol Lett 2002;135:79-87.
90. Chen F, Lu Y, Zhang Z, Vallyathan V, Ding M, Castranova V, Shi X. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 2001;276:11414-11419.
91. Bajenova O, Tang B, Pearse R, Feinman R, Childs BH, Michaeli J. RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Apoptosis 2004;9:561-571.
92. Yi J, Gao F, Shi G, Li H, Wang Z, Shi X, Tang X. The inherent cellular level of reactive oxygen species: One of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 2002;7:209-215.
93. Yeh JY, Cheng LC, Ou BR, Whanger DP, Chang LW. Differential influences of various arsenic compounds on glutathione redox status and antioxidative enzymes in porcine endothelial cells. Cell Mol Life Sci 2002;59:1972-1982.
94. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999;81:796-799.
95. Huang XJ, Wiernik PH, Klein RS, Gallagher RE. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 1999;16:58-64.
96. Kroemer G, de The H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999;91:743-745.
97. Adams JM, Cory S. The bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-1326.
98. Halicka HD, Smolewski P, Darzynkiewicz Z, Dai W, Traganos F. Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell Cycle 2002;1:201-209.
99. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001;98:3762-3769.
100. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002;62:529-538.
101. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, Pietenpol JA. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 1998;273:30777-30784.
102. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999;59:776-780.
103. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, Chen GQ. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 2003;17:1333-1337.
104. Li X, Ding X, Adrian TE. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 2003;27: 174-179.
105. Pan J, Xu G, Yeung SC. Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab 2001;86:4731-4740.
106. Yuan SY, Hsu SL, Tsai KJ, Yang CR. Involvement of mitochondrial pathway in Taxol-induced apoptosis of human T24 bladder cancer cells. Urol Res 2002;30:282-288.
107. Ofir R, Seidman R, Rabinski T, Krup M, Yavelsky V, Weinstein Y, Wolfson M. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ 2002;9:636-642.
108. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
109. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by APO-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-12690.
110. Marsters SA, Sheridan JP, Donahue J, Pitti RM, Gray CL, Goddard AD, Bauer KD, Ashkenazi A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr Biol 1996;6:1669-1676.
111. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998;281:1305-1308.
112. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of APO2/TRAIL-induced apoptosis in human melanoma. J Immunol 1998;161:2833-2840.
113. Wu GS, Burns TF, McDonald 3rd, ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, el-Deiry WS. KILLER/DR5 is a DNA damage-inducible, p53 regulated death receptor gene. Nat Genet 1997;17:141-143.
114. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor related apoptosis inducing ligand in vitro and in vivo. Cancer Res 2000;60:847-853.
115. Gliniak B, Le T. Tumor necrosis factor-related apoptosis inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153-6158.
116. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000;97:1754-1759.
117. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-446.
118. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, Costantini P, Ferri KF, Irinopoulou T, Prevost MC, Brothers G, Mak TW, Penninger J, Earnshaw WC, Kroemer G. Two distinct pathways leading to nuclear apoptosis. J Exp Med 2000;192:571-580.
119. Ye H, Cande C, Stephanou NC, Jiang S, Gurbuxani S, Larochette N, Daugas E, Garrido C, Kroemer G, Wu H. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol 2002;9:680-684.
120. Ravagnan I, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T, Jäättelä M, Penninger JM, Garrido C, Kroemer G. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 2001;3:839-843.
121. Cande C, Cecconi F, Dessen P, Kroemer G. Apoptosis-inducing factor (AIF): Key to the conserved caspase-independent pathways of cell death? J Cell Sci 2002;115: 4727-4734.
122. Lipton SA, Bossy-Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002;111:147-150.
123. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001;264:56-66.
124. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002;14:86-91.
125. Moll UM, Zaika A. Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 2001;493:65-69.
126. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803-1815.
127. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2002;29(Pt 6):684-688.
128. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;7(102):33-42.
129. Henry H, Thomas A, Shen Y, White E. Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene 2002;21:748-760.
130. La Rosee P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002;30:729-737.
131. Porosnicu M, Nimmanapalli R, Nguyen D, Worthington E, Perkins C, Bhalla KN. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 2001;15:772-778.
132. Lew YS, Kolozsvary A, Brown SL, Kim JH. Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res 2002;62:4202-4205.
133. Chun YJ, Park IC, Park MJ, Woo SH, Hong SI, Chung HY, Kim TH, Lee YS, Rhee CH, Lee SJ. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). FEBS Lett 2002;519:195-200.
134. Lai YL, Chang HH, Huang MJ, Chang KH, Su WH, Chen HW, Chung CH, Wang WY, Lin LH, Chen YJ. Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer - a pilot study. Anticancer Drugs 2003;14:825-828.
135. Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, Chaudary NI, Pervaiz H, Gallegos JA, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N, Candoni A, Singer J, Nucifora G. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 2004;28:791-803.
136. Anderson KC, Boise LH, Louie R, Waxman S. Arsenic trioxide in multiple myeloma: Rationale and future directions. Cancer J 2002;8:12-25.
137. Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004;125:470-476.
138. Borad MJ, Swift R, Berenson JR. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 2005;19:154-156.
139. Berenson JR, Swift RA, Ferretti D, Purner MB. A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma. Clin Lymphoma 2004;5:130-134.
140. Campbell RA, Chen H, Zhu D, Santos JC, Bonavida B, Pang S, Said J, Berenson JR. Arsenic trioxide shows synergistic anti-myeloma effects when combined with bortezomib and melphalan in vitro and helps overcome resistance of multiple myeloma cells to these treatments in vivo. Blood 2004;102:p666A.